Back to Journals » OncoTargets and Therapy » Volume 9

Expression and prognostic significance of unique ULBPs in pancreatic cancer

Authors Chen J, Zhu X, Xu H, Fang H, Zhao J

Received 4 March 2016

Accepted for publication 6 July 2016

Published 25 August 2016 Volume 2016:9 Pages 5271—5279

DOI https://doi.org/10.2147/OTT.S107771

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 5

Editor who approved publication: Professor Min Li


Jiong Chen,1,2,* Xing-Xing Zhu,1,2,* Hong Xu,1,2 Heng-Zhong Fang,1,2 Jin-Qian Zhao1,2

1Department of General Surgery, Anhui Provincial Hospital, Anhui Medical University, 2Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, People’s Republic of China

*These authors contributed equally to this work

Background: Pancreatic cancer is one of the most lethal cancers worldwide, due to the lack of efficient therapy and difficulty in early diagnosis. ULBPs have been shown to behave as important protectors with prognostic significance in various cancers.
Materials and methods: Immunohistochemistry and enzyme-linked immunosorbent assays were used to explore the expression of ULBPs in cancer tissue and in serum, while survival analysis was used to evaluate the subsequent clinical value of ULBPs.
Results: Statistics showed that high expression of membrane ULBP1 was a good biomarker of overall survival (18 months vs 13 months), and a high level of soluble ULBP2 was deemed an independent poor indicator for both overall survival (P<0.001) and disease-free survival (P<0.001).
Conclusion: ULBP1 provides additional information for early diagnosis, and soluble ULBP2 can be used as a novel tumor marker to evaluate the risk of pancreatic cancer patients.

Keywords: pancreatic cancer, NKG2D ligands, prognostic marker, cancer immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]